Industry
Biotechnology
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Loading...
Open
11.94
Mkt cap
1.2B
Volume
940K
High
12.36
P/E Ratio
-23.77
52-wk high
18.51
Low
11.87
Div yield
N/A
52-wk low
5.02
Portfolio Pulse from
December 12, 2024 | 7:45 pm
Portfolio Pulse from
November 13, 2024 | 2:00 pm
Portfolio Pulse from
November 13, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Insights
October 08, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 2:50 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 12:10 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.